NRBO NeuroBo Pharmaceuticals Inc.

17.51
-0.35  -2%
Previous Close 17.86
Open 17.65
Price To Book -10.68
Market Cap 10,918,431
Shares 623,554
Volume 16,589
Short Ratio
Av. Daily Volume 26,604
Stock charts supplied by TradingView

NewsSee all news

  1. NeuroBo Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

    NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today announced that it will present at Biotech Showcase 2020, to

  2. NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger

    - Shares of the Combined Company, NeuroBo Pharmaceuticals, Began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019 - NeuroBo Pharmaceuticals to Focus on Advancing Clinical Stage Pipeline for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b primary endpoint met - June 28, 2018.
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b data released June 28, 2017 - primary endpoint met.
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)
Phase 2 top-line released June 26, 2019.
Gemcabene
Familial Partial Lipodystrophy (FPL)
Phase 3 trial planned 1H 2020.
NB-01
Diabetic neuropathic pain (DNP)
Phase 3 trial planned.
Gemcabene
Familial Partial Lipodystrophy (FPL)

Latest News

  1. NeuroBo Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

    NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today announced that it will present at Biotech Showcase 2020, to

  2. NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger

    - Shares of the Combined Company, NeuroBo Pharmaceuticals, Began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019 - NeuroBo Pharmaceuticals to Focus on Advancing Clinical Stage Pipeline for